Helix Biomedix Research could hold answers to global antibiotic resistance crisis.BATON ROUGE, La.--(BUSINESS WIRE)--Oct. 19, 1995--Helix BioMedix Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). :HXBM) today announced the outcome of recent laboratory pre-clinical studies which indicate promising potential in combating the critical problem of antibiotic resistance antibiotic resistance, n the ability of certain strains of microorganisms to develop resistance to antibiotics. antibiotic resistance . Helix BioMedix Inc, is a biopharmaceutical company principally engaged in the development and commercialization of a new class of anti-infective and anti-cancer compounds. These compounds, proprietary to the company, are small bioactive bi·o·ac·tive adj. Of or relating to a substance that has an effect on living tissue. bioactive having an effect on or eliciting a response from living tissue. proteins called Cytoporins. Helix BioMedix Inc. has exclusive worldwide patent rights on this technology which was jointly developed by the company and Louisiana State University Louisiana State University and Agricultural and Mechanical College, generally known as Louisiana State University or LSU, is a public, coeducational university located in Baton Rouge, Louisiana and the main campus of the Louisiana State University System. (LSU LSU Louisiana State University LSU Large Subunit LSU La Salle University (Philadelphia, PA) LSU La Sierra University LSU Link State Update (OSPF) LSU Learning Support Unit ). Cytoporins are synthetic "designer" peptides (small proteins) derived primarily from compounds found in the immune defense system of the giant silk moth, Hyalophora cecropia. Cytoporins selectively disrupt the protective membrane of harmful bacteria while not adversely affecting healthy cells of the host. Research since 1986 by Helix BioMedix and LSU was originally directed toward the broad spectrum potential applications of Cytoporins in the treatment of diseases caused by bacteria, fungi, viruses and to their utilization as wound healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by and cancer therapy agents. Recent studies indicate that Cytoporins, when combined with currently available antibiotics act as powerful boosters which enhance antibiotic effectiveness by a factor of three to ten fold. Most importantly, mutant strains of bacteria which have developed immunity to most stand-alone antibiotics are effectively killed by co-therapy treatment with the proper combination of Cytoporins and the otherwise ineffective antibiotic(s). According to Keith P. Lanneau, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Helix BioMedix, "The synergistic effect Synergistic effect A violation of value-additivity in that the value of a combination is greater than the sum of the individual values. of Cytoporins with antibiotics now has emerged as the centerpiece of the Helix BioMedix/LSU research program. The past and current extensive use of antibiotics and the resulting antibiotic resistant bacteria strains that have developed pose a great threat to society. The specter of a real life "andromeda strain" scenario truly exists today." Dr. Donald R. Owen, Corporate and Scientific Director of Helix BioMedix, is conducting the ongoing research studies which establish that Cytoporins offer a potential solution to this serious health care problem. Helix BioMedix is accelerating its development work for commercial applications of its patented Cytoporin technology. CONTACT: Helix BioMedix Inc., Baton Rouge Keith P. Lanneau, 504/387-1112 or Harris, DeVille & Associates Jim Harris, 504/344-0381 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion